What is needed to get structured products accepted as mainstream?


Gary Dale, head of intermediary sales at Investec Structured Products, addresses the misconceptions blighting the investment plans.

Can we please stop using the term ‘structured products’? My reasoning is quite straightforward. The term ‘structured products’ conjures up many pre-conceived and often ill-conceived ideas that I am sure many advisers share and, being objective on the issue, I guess I would have to agree with some but certainly not all. For too long now the term ‘structured product’ has been over used to describe most non-traditional investment strategies without the necessary distinctions being applied to the variety of structures available. There are fundamental differences between structured deposit...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read